BridgeBio Pharma Inc.
BridgeBio Secures FDA Priority Review for BBP-418 in LGMD2I/R9
Summary
On May 27, 2026, BridgeBio Pharma, Inc. announced that the FDA has accepted for filing its New Drug Application (NDA) with Priority Review for BBP-418, an investigational oral therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The FDA's acceptance and priority review status, with a PDUFA target action date of November 27, 2026, marks a significant step towards potentially becoming the first approved treatment for LGMD2I/R9, addressing a critical unmet need in the treatment of this rare genetic disorder.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement